# Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

> **NCT04840485** · PHASE2,PHASE3 · COMPLETED · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 548 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** SHR-1314
- **DRUG:** SHR-1314
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04840485
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-09
- **Primary completion:** 2023-11-03
- **Final completion:** 2024-02-28
- **Target enrollment:** 548 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840485, "Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04840485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*